Ring Containing Patents (Class 514/559)
  • Patent number: 10808005
    Abstract: Provided are use of a compound of Formula I as a ligand of orphan nulear receptor Nur77, and in the prevention or treatment of a orphan nulear receptor Nur77 associated disease,
    Type: Grant
    Filed: July 4, 2017
    Date of Patent: October 20, 2020
    Assignee: IXMEDICINE (XIAMEN) BIOLOGICAL TECHNOLOGY COMPANY LIMITED
    Inventors: Xiaokun Zhang, Xiangzhi Lin, Ying Su, Zhiping Zeng, Mengjie Hu, Qiang Luo, Yi Zhu, Alitongbieke Gulimiran
  • Patent number: 10517869
    Abstract: The present invention provides an aqueous ophthalmic composition comprising an alpha-2 adrenergic receptor agonist and a non-ionic cellulosic polymer, the solution having a pH less than 6.5. The present invention also provides an aqueous ophthalmic composition comprising an alpha-2 adrenergic receptor agonist and a benzododecinium halide. Also provided are methods of manufacture, use and method of reducing intraocular pressure in the patient in need thereof.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: December 31, 2019
    Assignee: SENTISS PHARMA PRIVATE LIMITED
    Inventors: Mandar V. Shah, Deepak Bahri
  • Patent number: 10240112
    Abstract: The present disclosure is directed to compositions including a microemulsion comprising a blend of lecithin, a co-surfactant, and a salt of an acidifier, an ester of an acidifier, or combinations thereof. Uses of the compositions are also disclosed.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: March 26, 2019
    Assignee: Archer Daniels Midland Company
    Inventor: Shireen Baseeth
  • Patent number: 10226435
    Abstract: The present invention provides methods of treating humans and animals with terpenes and terpenoids in order to restore the stratum granulosum and stratum corneum and treat a dermatological disease, such as, for instance atopic dermatitis. More specifically it provides terpenes and terpenoids such as monoterpenoids, sesquiterpenes and norisoprenoids as ingredients that work to restore and thicken the stratum granulosum and stratum corneum and treat a dermatological disease. Terpenes and terpenoid compounds support the cell proliferation, cell differentiation, growth of skin, skin tissue and keratinocytes by upregulating genes for loricrin filaggrin, caspase 14, hornerin and other late cornified envelope components and vascular endothelial growth factor (VEGF) and downregulation of matrix metalloproteinases. Both terpenes and terpenoids may be applied topically or orally at oral or topical concentrations from about 0.
    Type: Grant
    Filed: June 6, 2012
    Date of Patent: March 12, 2019
    Assignees: New York University, BIOKEYS FOR FLAVORS, LLC
    Inventors: Fredric J. Burns, Ivica Labuda
  • Patent number: 9623062
    Abstract: The present invention provides a composition for skin regeneration including chamomile hydrosol prepared by vacuum distillation as an active ingredient. The composition for skin regeneration including camphor or chamomile hydrosol prepared by vacuum distillation, which contains the camphor, exhibits to excellent skin regeneration ability to promote proliferation and migration of skin cells, and simultaneously include only components derived from natural herbal plants, and thus can be used in various forms such as medicine, quasi-drugs, cosmetics, and food materials without any of side effects.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: April 18, 2017
    Assignees: Jeju National University Industryacademic Cooperation Foundation, Urban Farmers Co., Ltd.
    Inventors: Somi Kim, Moonjae Cho
  • Patent number: 9517218
    Abstract: In various embodiments, methods and compositions for treating Raynaud's disease and Raynaud's phenomenon are provided. Topical administration of a semisolid composition comprising a prostaglandin E1 compound provides the desired relief of the Raynaud's disease or Raynaud's phenomenon without the possible complications of systemic administration. The semisolid composition can be administered as needed, or in a regimen of several doses per day.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: December 13, 2016
    Assignee: NEXMED HOLDINGS, INC.
    Inventors: Daniel W. Frank, Richard Martin, Bassam B. Damaj
  • Patent number: 9463182
    Abstract: The use, as a dermatological or cosmetic ingredient, of compounds capable of transiently interacting with the AhR receptor (aryl hydrocarbon receptor) as agents for modulating skin functions such as sebaceous function, skin healing, skin atrophy termed “dermatoporosis”, estrogen deprivation and defense against infection, without inducing other toxic effects of the TCDD type. The compounds that interact the AhR receptor are chosen in that they have a metabolism favorable to the dissociation of these effects, in particular by virtue of in situ production from a precursor and/or metabolization in situ.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: October 11, 2016
    Assignee: THESAN PHARMACEUTICALS, INC.
    Inventor: Jean Hilaire Saurat
  • Patent number: 9169190
    Abstract: Described herein are methods for making retinoids. Also described herein are retinoids and methods of use thereof.
    Type: Grant
    Filed: April 4, 2013
    Date of Patent: October 27, 2015
    Assignee: The UAB Research Foundation
    Inventors: Wayne J. Brouillette, Donald D. Muccio, Venkatram Reddy Atigadda, John M. Ruppert, Susan M. Lobo Ruppert
  • Patent number: 9168219
    Abstract: Provided are compositions comprising an extract of Paulownia tomentosa wood and methods of use thereof.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: October 27, 2015
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Simarna Kaur, Khalid Mahmood, Claude Saliou, Michael Southall
  • Patent number: 9012503
    Abstract: Disclosed is an ophthalmic composition containing (A) not less than 50,000 units/100 mL of vitamin A, (B) not less than 0.4 W/V % of a polyoxyethylene polyoxypropylene glycol, and (C) trometamol.
    Type: Grant
    Filed: June 25, 2009
    Date of Patent: April 21, 2015
    Assignee: Lion Corporation
    Inventors: Nobuhito Tabuchi, Chieko Inoue, Manabu Hattori, Miyuki Miyake, Hazuki Tsutsui
  • Publication number: 20150098918
    Abstract: Stable cream gel dermatological/cosmetic compositions useful, e.g., for the treatment of acne vulgaris, contain, formulated into a physiologically acceptable medium, a homogeneous dispersion of at least one dispersed retinoid, dispersed benzoyl peroxide, at least one lipophilic compound and at least one gelling agent.
    Type: Application
    Filed: December 15, 2014
    Publication date: April 9, 2015
    Inventors: Claire MALLARD, Fabienne LOUIS, Emmanuelle At GUILLET
  • Patent number: 8999400
    Abstract: An aqueous disinfecting solution having a pH of from about 0.5 to about 6 consists essentially of hydrogen peroxide in a concentration of from about 0.05 to about 8 w/w % of the total solution, at least one anionic surfactant in a concentration of from about 0.02 to about 8 w/w % of the total solution, and at least one additional ingredient chosen from benzyl alcohol, an alcohol comprising one to six carbon atoms, and mixtures thereof, in a concentration of from about 0.1 to about 10 w/w % of the total solution.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: April 7, 2015
    Assignee: Virox Technologies Inc.
    Inventors: Jose A. Ramirez, Navid Omidbakhsh
  • Patent number: 8993626
    Abstract: The use of sterculic acid, and the pharmaceutically acceptable salt forms thereof, described for the treatment of inflammation, in particular, 7-ketocholesterol induced inflammation, 7-ketocholesterol toxicity, and unregulated angiogenesis.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: March 31, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Ignacio R. Rodriguez, Jiahn-Dar Huang, Juan A. Amaral, Jung Wha Lee, William Samuel, Ignacio Marcos Larrayoz
  • Publication number: 20150079182
    Abstract: A topical composition which includes a silica microspheres and an active ingredient in the amount of 0.01 to 15.0% w/w wherein the active ingredient is selected from adapalene, an antibiotic, tazarotene, tretinoin, a retinoid, or any combination thereof. The topical composition may also include benzoyl peroxide as an active ingredient. The topical compositions provide sustained release of the active ingredient so as to reduce skin irritation.
    Type: Application
    Filed: November 24, 2014
    Publication date: March 19, 2015
    Inventors: Marina Shevachman, Amira Ze' Evi, Eilon Asculai, Batella Binyaminovich, Nir Avram
  • Publication number: 20150080353
    Abstract: The subject invention relates to compositions and methods useful for the in vivo delivery of substantially water-insoluble drugs, like taxol. The use of specific composition and preparation conditions enables the reproducible production of unusually water-soluble formulation, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a re-dispersible dry powder comprising nanoparticles of drug. The innovation is also based on the fact that complementary partner is also an active drug but may have a different mode action with respect to primary molecule of the hybrid drug. The complementary molecule has multiple properties like antioxidant, antimicrobial, anti-inflammatory, anti-allergic, cox-2 inhibitors, etc. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable.
    Type: Application
    Filed: November 6, 2014
    Publication date: March 19, 2015
    Inventors: Mewa SINGH, Maninder SANDHU
  • Publication number: 20150071984
    Abstract: Controlled release vascular implants, such as vascular grafts, stents, wraps, and gels comprising a biocompatible polymer and all trans retinoic acid (ATRA), or its derivatives, can be used to treat, prevent, or inhibit thrombosis and/or neointimal hyperplasia which may otherwise be induced by prosthetic implantation. In particular, the implants herein can inhibit smooth muscle cell proliferation, neointimal hyperplasia, and upregulate antithrombotic genes and nitric oxide production in the vasculature. Further, the implants are capable of delivering controlled and predictable localized concentrations of ATRA.
    Type: Application
    Filed: November 18, 2014
    Publication date: March 12, 2015
    Inventors: Guillermo A. Ameer, Melina Kibbe, Antonio Webb
  • Publication number: 20150057351
    Abstract: A method for treating neuropathic pain in a mammalian subject, which comprises administering an effective amount of a fatty acid derivative, is provided.
    Type: Application
    Filed: August 20, 2014
    Publication date: February 26, 2015
    Applicant: SUCAMPO AG
    Inventor: Ryuji UENO
  • Publication number: 20150051259
    Abstract: Treatment and diagnostic methods are provided for pulmonary disease, including chronic obstructive pulmonary disease. Various pro-inflammatory mediators are elevated in a model of COPD that can be used predict the presence of COPD and/or subtypes of COPD in human patients. Profiles of these mediators can also predict the responsiveness of some patients to certain therapies, including thromboxane receptor antagonist treatment. Methods are provided for diagnosing a subject as a pulmonary disease candidate that include determining leukocyte expression in the subject of at least one pro-inflammatory mediator and identifying the subject as a pulmonary disease candidate when leukocyte expression in the subject of the pro-inflammatory mediator is increased compared to leukocyte expression of the pro-inflammatory mediator in a healthy individual. The pulmonary disease candidate can also be treated by administering a therapeutically effective amount of a thromboxane receptor antagonist.
    Type: Application
    Filed: April 9, 2013
    Publication date: February 19, 2015
    Inventors: John M. Hartney, Raul M. Torres, Roberta Pelanda
  • Publication number: 20150044278
    Abstract: The invention features methods of treating a proliferative disorder characterized by elevated Pin1 marker levels and/or reduced Pin1 Ser71 phosphorylation in a subject by administering a retinoic acid compound. Additionally, the invention features methods of treating proliferative disorders (e.g., proliferative disorders characterized by elevated Pin1 marker levels) by administering a retinoic acid compound in combination with another anti-proliferative compound. Finally, the invention also features methods including high-throughput screens for discovering and validating Pin1 inhibitors.
    Type: Application
    Filed: July 17, 2014
    Publication date: February 12, 2015
    Inventors: Kun Ping LU, Shuo Wei, Xiao Zhen Zhou
  • Patent number: 8952064
    Abstract: An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: February 10, 2015
    Assignee: Galephar Pharmaceutical Research, Inc.
    Inventors: Francis Vanderbist, Cécile Servais, Philippe Baudier
  • Patent number: 8946291
    Abstract: A method of treating melanoma in a subject comprising administering an amount of SOX9 sufficient to treat melanoma is disclosed. A method of treating a hyperpigmentary condition in a subject comprising administering an amount of inhibitor of SOX9 activity sufficient to treat the condition is disclosed. A method of treating melanoma in a subject comprising administering an amount of SOX9 sufficient to treat melanoma is disclosed. A method of treating melanoma in a subject comprising increasing the amounts of retinoic acid and SOX9 in the subject by amounts sufficient to treat melanoma. A method of treating melanoma in a subject comprising administering an amount of prostaglandin D2 and retinoic acid sufficient to treat cancer is disclosed. A method of sensitizing a melanoma cell to RA comprising administering an amount of SOX9 sufficient to decrease PRAME expression is disclosed.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: February 3, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Vincent J. Hearing, Thierry Passeron
  • Patent number: 8945594
    Abstract: A formulation for topical use having a filmogenic (peel-off) action for professional and home use, containing high concentrations of Retinoic acid, the method of production and use thereof in the treatment of acne, wrinkles, hyperpigmentations, psoriasis and all imperfections linked to keratinization disorders. The composition also comprises octyldodecyl octyldodecanoate, and polyvinyl alcohol. The composition is in the form of a face mask (pack).
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: February 3, 2015
    Assignee: Laboratori Farmaceutici Krymi S.p.A.
    Inventors: Rocco Crimi, Raniero Cozzi
  • Patent number: 8940794
    Abstract: In various embodiments, methods and compositions for treating Raynaud's disease and Raynaud's phenomenon are provided. Topical administration of a semisolid composition comprising a prostaglandin E1 compound provides the desired relief of the Raynaud's disease or Raynaud's phenomenon without the possible complications of systemic administration. The semisolid composition can be administered as needed, or in a regimen of several doses per day.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: January 27, 2015
    Assignee: Nexmed Holdings, Inc.
    Inventors: Daniel W. Frank, Richard Martin, Bassam B. Damaj
  • Publication number: 20150011633
    Abstract: Pharmaceutical formulations containing lipoic acid derivatives are made.
    Type: Application
    Filed: March 27, 2014
    Publication date: January 8, 2015
    Applicant: Cornerstone Pharmaceuticals, Inc.
    Inventors: Robert G. L. Shorr, Robert J. Rodriguez, Rajinder Bhasin
  • Publication number: 20150005381
    Abstract: In one embodiment, provided is a composition including a prostaglandin compound for modulating stem cell proliferation and/or differentiation in a mammalian subject. In another embodiment, the instant application is directed to a composition which includes a prostaglandin compound for modulating proliferation and/or differentiation of stem cells of a mammalian subject, in which the stem cells are contacted directly or indirectly with the composition of the invention.
    Type: Application
    Filed: September 16, 2014
    Publication date: January 1, 2015
    Applicant: SUCAMPO AG
    Inventors: Ryuji UENO, Sachiko KUNO
  • Patent number: 8920821
    Abstract: The present invention relates to a topical composition which includes a bioactive drug formulated with silica in the form of microspheres, or drugs in a combination with the silica microspheres in an oily suspension, gel or emulsion. The topical compositions of the invention provide sustained release of a bioactive drug so as to reduce skin irritation.
    Type: Grant
    Filed: April 12, 2007
    Date of Patent: December 30, 2014
    Assignee: Perrigo Israel Pharmaceuticals Ltd.
    Inventors: Nir Avram, Marina Shevachman, Amira Ze'evi, Eilon Asculai, Batella Binyaminovich
  • Publication number: 20140377384
    Abstract: The invention encompasses a formulation for hair loss prevention comprising a mixture of water and at least one nonpolar aprotic organic solvent and at least one hair loss preventive ingredient known to inhibit the hormonal mechanism underlying androgenetic hair loss and methods of using the same.
    Type: Application
    Filed: September 14, 2014
    Publication date: December 25, 2014
    Inventor: Giuseppe Trigiante
  • Publication number: 20140348938
    Abstract: The present invention relates to a simple and convenient process for preparing solid lipid sustained release nanoparticles for delivery of drugs/vitamins, preferably fat soluble vitamins and more specifically Vitamin D3 and retinoic acid (RA). The process involves microemulsion technique. The nanoparticles of Vitamin D3 and RA obtained by the process of the present invention have utility in treatment of diseases like tuberculosis. Use may be extended to other diseases like AMD, diabetic retinopathy, cancers, hyperpigmentation, acne, and osteoporosis.
    Type: Application
    Filed: January 9, 2013
    Publication date: November 27, 2014
    Inventors: Indu Pal Kaur, Manoj Kumar Verma
  • Publication number: 20140350106
    Abstract: Compositions and methods for urea silicone gels for treating skin conditions that may benefit from barrier protection and from urea silicone gel ability to return water balance to the skin are disclosed. Skin conditions that may be treated with urea silicone gel may be excessive dryness, insect bites, keloids and scars, among others. Disclosed urea silicone gel may include micronized urea USP, an anhydrous silicone base, and a PEG ointment base, among other ingredients. Anhydrous silicone base may include Amazonian oils such as pracaxi oil and seje oil, which are rich in oleic, linolenic, linoleic acids, and sterols, particularly beta-sitosterol and stigmasterol that may increase skin permeability to urea. PEG ointment base may be water-washable and includes meadowsweet extract. Additionally, PEG urea silicone gel may provide occlusion, and may maintain a moist environment within the skin condition which allows optimal healing. Pain also may be decreased by maintaining a moist environment.
    Type: Application
    Filed: May 22, 2013
    Publication date: November 27, 2014
    Applicant: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
    Inventor: Fabiana Campanati Banov
  • Publication number: 20140343145
    Abstract: Disclosed herein are methods for detecting the presence of an isocitrate dehydrogenase mutation in a sample from a subject. Also disclosed are methods diagnosing and treating subjects having a cancer including determining whether the cancer may likely be treated with one or more retinoids.
    Type: Application
    Filed: November 27, 2012
    Publication date: November 20, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Arthur P. Chou, Albert Lai, Reshmi Chowdhury, Weidong Chen
  • Patent number: 8877762
    Abstract: The present disclosure relates to compositions containing certain pyrimidine compounds such as minoxidil and/or certain pyrimidine sulfate (inner salt) compounds such as minoxidil sulfate and especially compositions containing pyrimidine compounds in combination with an admixtures comprising at least one antioxidant, at least one organic acid and a select fatty acid mixture. The present disclosure also relates to use of the compositions to grow and/or regrow hair and/or prevent hair loss in mammals and particularly in humans.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: November 4, 2014
    Assignee: McNeil-PPC, Inc.
    Inventors: Longsheng Hu, Virginia Streusand Goldman, Josephine A. Minerva, Susan Wendling
  • Publication number: 20140322148
    Abstract: Described herein are topical oil-based formulations that find use in the treatment of alopecia, i.e., hair loss, and in the promotion of hair growth.
    Type: Application
    Filed: November 20, 2012
    Publication date: October 30, 2014
    Inventor: Adrianna Janell JACKSON
  • Publication number: 20140323457
    Abstract: The present invention relates to beta-O/S/N fatty acids and derivatives thereof, in particular the compounds of formula (I) as described and defined herein, and their pharmaceutical use, including their use in the treatment or prevention of bacterial as well as protozoan infections, in particular the treatment or prevention of infections with Gram-positive and/or Gram-negative bacteria and infectious diseases caused by and/or related to Gram-positive and/or Gram-negative bacteria. The invention further relates to the use of these compounds for preventing or eliminating biofilms.
    Type: Application
    Filed: December 6, 2012
    Publication date: October 30, 2014
    Inventors: Thomas Böttcher, Vadim Korotkov, Katrin Lorenz-Baath, Oliver Baron, Stephan Sieber
  • Publication number: 20140303251
    Abstract: The present invention provides, in one embodiment, a method of inhibiting apoptosis in kidney epithelial cells after acute injury by modulating/inhibiting Nur77 induction/expression or function/activity in the cells. The invention further provides a method of preventing or treating an acute kidney injury in a subject in need thereof, comprising administering to the subject an effective amount of a retinoic acid or retinoic acid derivative, and a method of preserving a kidney for transplant, comprising contacting the kidney with a solution that comprises a retinoic acid or a, retinoic acid derivative.
    Type: Application
    Filed: January 31, 2012
    Publication date: October 9, 2014
    Applicants: Beth Israel Deaconess Medical Center, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Terry B. Strom, Savithri Balasubramanian, Benjamin D. Humphreys
  • Publication number: 20140271875
    Abstract: The present invention provides topical dermal compositions including microsphere encapsulated isotretinoin. Pharmaceutically acceptable salts, esters, or amides of isotretinoin are also contemplated for use in the practice of the invention. The compositions of the invention are useful for treating a variety of conditions associated with excess sebum production, such as, for example, acne.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: Allergan, Inc.
    Inventors: John E. Donello, Rong Yang
  • Patent number: 8835496
    Abstract: The present invention relates to a human beta-defensin inducing agent that comprises at least one fat or oil of an essential fatty acid triglyceride or a derivative thereof as the main active ingredient. It also relates to cosmetic, dermatological and pharmacological formulations comprising the at least one fat or oil.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: September 16, 2014
    Assignee: Croda International PLC
    Inventors: Anthony Vincent Rawlings, Debra Louise Jones
  • Publication number: 20140235665
    Abstract: An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in a ratio of bi-cyclic/mono-cyclic structure of at least 1:1. The halogenated-bi-cyclic compound is represented by Formula (I): where X1 and X2 are preferably both fluorine atoms. The composition can be used to treat constipation without substantive side-effects, such as stomachache.
    Type: Application
    Filed: April 30, 2014
    Publication date: August 21, 2014
    Applicant: SUCAMPO AG
    Inventor: Ryuji UENO
  • Publication number: 20140234420
    Abstract: The present invention describes methods and compositions for treating diverse dermatological conditions, including acne and psoriasis, using zein containing nanocarrier devices for topical delivery of methotrexate, retinoic acid and benzoyl peroxide to select targets in the skin.
    Type: Application
    Filed: August 14, 2013
    Publication date: August 21, 2014
    Inventors: Omathanu P. Perumal, Ranjith Kumar Averineni
  • Publication number: 20140235562
    Abstract: A method of treating an ocular disorder in a subject includes administering to the subject a therapeutically effective amount of an agent that modulates at least one target in a signaling cascade associated with light induced retinal degeneration, aberrant all-trans-retinal accumulation, and/or generation of reactive oxygen species (ROS).
    Type: Application
    Filed: April 25, 2014
    Publication date: August 21, 2014
    Inventors: Krzysztof Palczewski, Yu Chen
  • Patent number: 8808755
    Abstract: A skin disinfectant in ready-to-use concentrated liquid or dry powdered form. Ready-to-use liquid forms have a pH of from about 2 to about 6 and include: (a) hydrogen peroxide in a concentration of from about 0.01 to about 4% w/w of the solution; (b) at least one surfactant chosen from imidazoline derivatives, alkyl betaines, alkyl amidopropyl betaine amides, alkyl amidopropyl betaines, alkylsulfo betaines, amine oxides and derivatives thereof in a concentration of from about 0.01 to about 15% w/w of the solution; (c) at least one hydrogen peroxide stabilizer in a concentration of from about 0.01 to about 4% w/w of the solution; (d) at least one member chosen from cyclic carboxylic acids and salts thereof in a concentration of from about 0.01 to about 4% w/w of the solution; and (e) at least one skin conditioning agent in a concentration of from about 0.01 to about 10% w/w of the solution.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: August 19, 2014
    Assignee: Virox Technologies Inc.
    Inventor: Navid Omidbakhsh
  • Patent number: 8802874
    Abstract: The invention features methods for the preparation of naturally occurring trihydroxy polyunsaturated eicosanoids and their structural analogs. The invention further provides new derivatives and analogs of trihydroxy polyunsaturated eicosanoids that can be prepared according to these methods. The invention also provides compositions and methods using trihydroxy polyunsaturated eicosanoid derivatives for the prevention, amelioration and treatment of a variety of diseases or conditions associated with inflammation or inflammatory response, autoimmune diseases, rheumatoid arthritis, cardiovascular diseases, or abnormal cell proliferation or cancer.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: August 12, 2014
    Assignee: University of Southern California
    Inventor: Nicos A. Petasis
  • Patent number: 8802120
    Abstract: Bioactive agrichemical concentrates and compositions having improved bioactivity comprising combinations of acid solutions and conventional bioactive agrichemical actives or formulations.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: August 12, 2014
    Assignee: Sciessent LLC
    Inventor: Joseph J. Crudden
  • Patent number: 8802881
    Abstract: Benzolipoxin analogs, methods of their preparation and pharmaceutical compositions containing the compounds are provided. The compounds and compositions are useful in methods for treatment of various diseases, including, inflammation, autoimmune disease and abnormal cell proliferation.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: August 12, 2014
    Assignee: University of Southern California
    Inventor: Nicos A. Petasis
  • Publication number: 20140219957
    Abstract: The invention features methods of treating an immune disorder characterized by elevated Pin1 marker levels in a subject by administering a retinoic acid compound. Additionally, the invention features methods of treating immune disorders (e.g., immune disorders characterized by elevated Pin1 marker levels) by administering a retinoic acid compound in combination with an anti-inflammatory, anti-viral, or anti-microbial compound.
    Type: Application
    Filed: May 29, 2012
    Publication date: August 7, 2014
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Kun Ping Lu, Adrian Tun-Kyi, Greg Finn
  • Publication number: 20140212474
    Abstract: Compositions that can include a carrier, targeting agent, and therapeutic agent are disclosed herein. The therapeutic agent may have a therapeutic activity such as inhibiting fibrosis within a target organ or tissue or inhibiting the growth of a cancer cell.
    Type: Application
    Filed: January 29, 2014
    Publication date: July 31, 2014
    Applicant: Nitto Denko Corporation
    Inventors: Yoshiro Niitsu, Lei Yu, Gang Zhao, Sang Van, Fu Chen
  • Publication number: 20140205661
    Abstract: A new pharmaceutical formulation for retinoid-containing soft gelatin capsules is disclosed. The new formulation comprises a soft gelatin capsule filled with a fill mass comprising a retinoid as an active ingredient, a natural vegetable oil, a partially hydrogenated natural vegetable oil and medium chain triglycerides. Optionally, the new formulation also comprises a natural wax. In a particularly preferred embodiment, the soft gelatin capsule comprises pig gelatin in the capsule shell in combination with the above fill mass.
    Type: Application
    Filed: February 27, 2014
    Publication date: July 24, 2014
    Applicant: GLAXO GROUP LIMITED
    Inventors: Günter DITZINGER, Bernhard GABRIEL, Anne-Hortense SCHMITT-HOFFMANN, Lutz WEVELSIEP
  • Publication number: 20140200274
    Abstract: In various embodiments, methods and compositions for treating Raynaud's disease and Raynaud's phenomenon are provided. Topical administration of a semisolid composition comprising a prostaglandin E1 compound provides the desired relief of the Raynaud's disease or Raynaud's phenomenon without the possible complications of systemic administration. The semisolid composition can be administered as needed, or in a regimen of several doses per day.
    Type: Application
    Filed: April 6, 2012
    Publication date: July 17, 2014
    Applicant: Nexmed Holdings, Inc
    Inventors: Daniel W. Frank, Richard Martin, Bassam B. Damaj
  • Publication number: 20140179630
    Abstract: The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
    Type: Application
    Filed: October 28, 2013
    Publication date: June 26, 2014
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Charles N. SERHAN, Bruce D. LEVY
  • Publication number: 20140170201
    Abstract: Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Also provided are bioresorbable nanoparticles prepared without the use of organic solvents, and methods for therapeutically using such bioresorbable nanoparticles.
    Type: Application
    Filed: September 30, 2013
    Publication date: June 19, 2014
    Applicants: Drexel University, The Children's Hospital of Philadelphia
    Inventors: Robert J. Levy, Boris Polyak, Michael Chorny, Ilia Fishbein, Ivan Alferiev, Gennady Friedman, Darryl Williams
  • Publication number: 20140163102
    Abstract: The present invention provides a medical dressing for respiratory epithelial cells comprising a biocompatible polymer and retinoic acid, wherein, based on total volume of the dressing, the polymer is 99% or more, and retinoic acid is 1% or less.
    Type: Application
    Filed: December 6, 2013
    Publication date: June 12, 2014
    Applicant: National Taiwan University
    Inventors: TAI-HORNG YOUNG, TSUNG-WEI HUANG, HSU-HSIEN CHANG